Abstract:Zhen Cheng, &ast Chunyu Hu, &ast Yalan Zhang, Jie Zhou, Jiayang Shi, Li Sun, Zongtao Chen Health Management Centre, First Affiliated Hospital of Army Medical University, Chongqing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zongtao Chen; Li Sun, Health Management Centre, First Affiliated Hospital of Army Medical University, No. 30, Gaotanyan Street, Shapingba District, Chongqing, People's Republic of China, Tel +86 2368765191 ; +86 2368765228, Email ; Purpose: The aim of this study was to comprehensively compare the predictive effect of 10 body fat indexes on MAFLD in different sex, age and BMI subgroups. Patients and Methods: A total of 5403 physical examination data were included and divided into the MAFLD group (N=2632) and non-MAFLD group (N=2771). The differences and correlation of 10 promising indicators between the two groups were compared, including fatty liver index (FLI), hepatic steatosis index (HSI), lipid accumulation product (LAP), visceral fat index (VAI), cardiometabolic index (CMI), body adiposity index (BAI), and triglyceride-glucose index (TyG), waist circumference index (WC), body mass index (BMI), waist to height ratio (WHtR). Logistic regression was used to analyze the risk of MAFLD under different adjustment conditions. The operating characteristic curve of different genders, BMI levels and age subgroups was plotted. Results: Male gender, smoking, alcohol drinking, and higher age are risk factors for MAFLD. In addition to BAI, the other 9 indicators had a high correlation with MAFLD, the area under the curve (AUC) value was > 0.7, and the prediction effect was better in females, BMI< 24 kg/m2, age < 35 years subgroup, among which FLI (AUC: 0.912, 95% CI: 0.905– 0.920), LAP (AUC: 0.894, 95% CI: 0.8866– 0.903), and HSI (AUC: 0.881, 95% CI: 0.872– 0.890) have better prediction effects. Conclusion: Our study confirmed the accuracy of body fat-related indexes in predicting MAFLD in people of different sexes, ages, and BMI levels. Among them, FLI, LAP and HSI have high predictive value and can be utilized as simple and cost-effective tools for screening MAFLD in clinical settings. Keywords: metabolic dysfunction-associated fatty liver disease, body fat index, metabolic index, cross-sectional study In 2022, an international panel of experts redefined non-alcoholic fatty liver disease (NAFLD) as metabolic dysfunction-associated fatty liver disease (MAFLD). 1 The prevalence of MAFLD is approximately 25% globally, affecting an estimated 173 to 310 million individuals in China. According to the latest data on the global burden of liver disease in 2019, the prevalence of MAFLD 25% in Europe and Japan. In China, the prevalence increased from 17% in 2003 to 22.4% in 2012. 2,3 In the United States, the prevalence of MAFLD has increased from 34.4% to 38.1% over the past decade. 4 Recently, the prevalence of MAFLD has increased annually and is trending younger. This condition can progress to hepatitis, liver cirrhosis, and liver cancer, posing a serious threat to health, 5 It has become a leading cause of liver disease burden in many countries and regions worldwide, representing a significant global public health challenge in the 21st century. 6,7 Therefore, the early and timely detection and treatment of MAFLD is crucial for delaying the progression of the disease. Currently, liver tissue biopsy is considered the gold standard for diagnosing MAFLD. However, its clinical use is limited due to its invasive nature. 8 Magnetic resonance imaging (MRI) and computed tomography (CT) are expensive non-invasive diagnostic methods, while the MAFLD Fibrosis Score and the Fibrosis 4 Index have limitations in predictive performance and risk stratification, 9 and the accuracy of diagnosis was affected by age and transaminase levels. 10 Although the commonly used ultrasound technique is safe, it is not highly effective for identifying subjects with a fat infiltration degree of less than 30%. Therefore, the rapid identification and diagnosis of MAFLD in a convenient and efficient manner hold significant health-economic importance for preventing and delaying the progression of MAFLD, as well as the occurrence of related complications. With the increasing trend of obesity and type 2 diabetes, More and more studies have confirmed that the occurrence of MAFLD is related to fat infiltration and metabolic processes in liver tissue, as well as insulin resistance (IR). The combination of lipid accumulation and metabolites, as well as the extent of lipid accumulation, is clinically significant for the diagnosis and evaluation of MAFLD. 11–13 Other stud -Abstract Truncated-

MAFLD fibrosis score: Using routine measures to identify advanced fibrosis in metabolic‐associated fatty liver disease

Maf-5 Predicts Liver Fibrosis Risk And Outcome In The General Population With Metabolic Dysfunction

Development and validation of a novel circulating fibroblast activation protein - based predictive model to improve fibrosis risk stratification in metabolic liver disease population

acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter Study

Metabolic Disorders Combined with Noninvasive Tests to Screen Advanced Fibrosis in Nonalcoholic Fatty Liver Disease

The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD

N-terminal Propeptide of Type 3 Collagen-Based Sequential Algorithm Can Identify High-Risk Steatohepatitis and Fibrosis in MAFLD

Optimizing Use of Nonalcoholic Fatty Liver Disease Fibrosis Score, Fibrosis-4 Score, and Liver Stiffness Measurement to Identify Patients With Advanced Fibrosis

Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease

Machine‐learning model comprising five clinical indices and liver stiffness measurement can accurately identify MASLD‐related liver fibrosis

Development and validation of a novel score for fibrosis staging in patients with chronic hepatitis B.

Performance Evaluation of a Novel Non-Invasive Test for the Detection of Advanced Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease

IDDF2023-ABS-0099 Fibrosis-4 Index Predicts Adverse Cardiovascular Outcomes among Patients Comorbid with MAFLD and Coronary Heart Disease

Mitochondria-derived Methylmalonic Acid is Associated with Advanced Fibrosis Risks in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): Results from the NHANES 1999–2004

Establishment and Evaluation of a Noninvasive Metabolism-Related Fatty Liver Screening and Dynamic Monitoring Model: Cross-Sectional Study

Comments on validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease

The Different Predictive Effects of Multiple Body Fat Indexes on Metabolic Dysfunction-Associated Fatty Liver Disease

Identifying and Linking Patients At Risk for MASLD with Advanced Fibrosis to Care in Primary Care

Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction‐associated steatotic liver disease – The Gut and Obesity in Asia (GO‐ASIA) Study

Accuracy of FibroTouch in Assessing Liver Steatosis and Fibrosis in Patients with Metabolic-Associated Fatty Liver Disease Combined with Type 2 Diabetes Mellitus.

MAFLD identifies patients with significant hepatic fibrosis better than MASLD